Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer

PURPOSE: We tested the hypothesis that Akt-Ser473 phosphorylation (pAkt) predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Yang, Sherry X., Costantino, Joseph P., Kim, Chungyeul, Mamounas, Eleftherios P., Nguyen, Dat, Jeong, Jong-Hyeon, Wolmark, Norman, Kidwell, Kelley, Paik, Soonmyung, Swain, Sandra M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2010
विषय:
Original Reports
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903333/
https://ncbi.nlm.nih.gov/pubmed/20479407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.1602
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन